CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues		$ 6,623	$ 5,724	$ 10,546	$ 10,758
Cost of revenues	[1]	3,914	3,213	6,495	6,125
Gross profit		2,709	2,511	4,051	4,633
Operating expenses:
Research and development, net		1,754	767	7,599	1,685
Sales and marketing		3,531	3,785	6,802	7,622
General and administrative		1,576	1,739	4,141	3,959
Impairment charges		0	2,783	0	2,783
Total operating expenses		6,861	9,074	18,542	16,049
Operating loss		(4,152)	(6,563)	(14,491)	(11,416)
Financial expense (income), net	[2]	7,357	(1)	7,805	(31)
Loss before income taxes		(11,509)	(6,562)	(22,296)	(11,385)
Taxes on income		10	0	16	11
Net loss		$ (11,519)	$ (6,562)	$ (22,312)	$ (11,396)
Net loss per ordinary share, basic		$ (4.12)	$ (7.01)	$ (10.09)	$ (12.59)
Net loss per ordinary share, diluted		$ (4.12)	$ (7.01)	$ (10.09)	$ (12.59)
Weighted average number of shares used in computing net loss per ordinary share, basic	[3]	2,796,621	935,785	2,210,280	904,881
Weighted average number of shares used in computing net loss per ordinary share, diluted	[3]	2,796,621	935,785	2,210,280	904,881

[1] Includes revenue sharing expense attributable to Oramed Pharmaceuticals Inc., a related party, of $97 for the three and six months ended June 30, 2026.

[2] Includes net financing expense comprised of interest expense and changes in fair value of warrant and derivative liabilities related to Oramed Pharmaceuticals Inc., a related party, of $7,074 and $7,470 for the three and six months ended June 30, 2026, respectively.

[3] Reflects the one-for-twelve reverse share split that became effective on February 24, 2026. See Note 8a to the condensed consolidated financial statements.